Artiva reports Q2 2026 results, RMAT for AlloNK in refractory RA, Phase 3 plan
Artiva said it will begin a Phase 3 trial of AlloNK plus rituximab in refractory rheumatoid arthritis in the second half of 2026 after FDA granted RMAT designation, with cash extending into 2029.
SEC filing